Now showing items 1-20 of 26

    • A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. 

      Minchom, A; Thavasu, P; Ahmad, Z; Stewart, A; Georgiou, A; O'Brien, MER; Popat, S; Bhosle, J; Yap, TA; de Bono, J; Banerji, U (2017-01)
      We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected ...
    • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. 

      Eggermont, AMM; Blank, CU; Mandala, M; Long, GV; Atkinson, V; Dalle, S; Haydon, A; Lichinitser, M; Khattak, A; Carlino, MS; Sandhu, S; Larkin, J; Puig, S; Ascierto, PA; Rutkowski, P; Schadendorf, D; Koornstra, R; Hernandez-Aya, L; Maio, M; van den Eertwegh, AJM; Grob, J-J; Gutzmer, R; Jamal, R; Lorigan, P; Ibrahim, N; Marreaud, S; van Akkooi, ACJ; Suciu, S; Robert, C
      BACKGROUND:The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate ...
    • Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. 

      Wongchenko, MJ; Ribas, A; Dréno, B; Ascierto, PA; McArthur, GA; Gallo, JD; Rooney, IA; Hsu, J; Koeppen, H; Yan, Y; Larkin, J (2018-07)
      The prognostic significance of programmed death ligand-1 (PD-L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the ...
    • Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. 

      Chau, I (2017-10)
      Gastrointestinal (GI) cancers are among the most deadly malignancies. Although serial incremental survival benefits have been made with cytotoxic chemotherapy with metastatic disease, a plateau of achievement has been ...
    • Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. 

      Brown, JS; Sundar, R; Lopez, J (2018-02)
      The idea that chemotherapy can be used in combination with immunotherapy may seem somewhat counterproductive, as it can theoretically eliminate the immune cells needed for antitumour immunity. However, much preclinical ...
    • Emerging biomarkers for PD-1 pathway cancer therapy. 

      Lim, JS; Sundar, R; Chénard-Poirier, M; Lopez, J; Yap, TA (2017-01)
      The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. ...
    • Encouraging results for PD-1 inhibition in gastric cancer. 

      Smyth, EC; Cunningham, D (2016-06)
    • From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. 

      Hussain, SA; Birtle, A; Crabb, S; Huddart, R; Small, D; Summerhayes, M; Jones, R; Protheroe, A (2018-12)
      Context A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials.Objective To ...
    • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 

      Brahmer, JR; Rodríguez-Abreu, D; Robinson, AG; Hui, R; Csőszi, T; Fülöp, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Zhang, J; Lubiniecki, GM; Deitz, AC; Rangwala, R; Reck, M (2017-12)
      Background In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer ...
    • Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. 

      Turkington, RC; Knight, LA; Blayney, JK; Secrier, M; Douglas, R; Parkes, EE; Sutton, EK; Stevenson, L; McManus, D; Halliday, S; McCavigan, AM; Logan, GE; Walker, SM; Steele, CJ; Perner, J; Bornschein, J; MacRae, S; Miremadi, A; McCarron, E; McQuaid, S; Arthur, K; James, JA; Eatock, MM; O'Neill, R; Noble, F; Underwood, TJ; Harkin, DP; Salto-Tellez, M; Fitzgerald, RC; Kennedy, RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group (2019-11)
      Objective Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability of a DNA damage immune response (DDIR) assay to predict response following ...
    • Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. 

      Maio, M; Hamid, O; Larkin, J; Covre, A; Altomonte, M; Calabrò, L; Vardhana, SA; Robert, C; Ibrahim, R; Anichini, A; Wolchok, JD; Giacomo, AMD (2020-08)
      The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to ...
    • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. 

      Mazieres, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, AB; Mezquita, L; Thai, AA; Mascaux, C; Couraud, S; Veillon, R; Van den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, TL; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, VW; Rothschild, SI; Bironzo, P; Martinez-Marti, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, RD; Wakelee, H; Camidge, DR; Zalcman, G; Novello, S; Ou, SI; Milia, J; Gautschi, O (2019-08)
      Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is ...
    • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. 

      Nava Rodrigues, D; Rescigno, P; Liu, D; Yuan, W; Carreira, S; Lambros, MB; Seed, G; Mateo, J; Riisnaes, R; Mullane, S; Margolis, C; Miao, D; Miranda, S; Dolling, D; Clarke, M; Bertan, C; Crespo, M; Boysen, G; Ferreira, A; Sharp, A; Figueiredo, I; Keliher, D; Aldubayan, S; Burke, KP; Sumanasuriya, S; Fontes, MS; Bianchini, D; Zafeiriou, Z; Teixeira Mendes, LS; Mouw, K; Schweizer, MT; Pritchard, CC; Salipante, S; Taplin, M-E; Beltran, H; Rubin, MA; Cieslik, M; Robinson, D; Heath, E; Schultz, N; Armenia, J; Abida, W; Scher, H; Lord, C; D'Andrea, A; Sawyers, CL; Chinnaiyan, AM; Alimonti, A; Nelson, PS; Drake, CG; Van Allen, EM; de Bono, JS (2018-10)
      Background Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection.Methods Defective mismatch repair (dMMR) status was determined by either loss ...
    • Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. 

      Ottaviano, M; Curvietto, M; Rescigno, P; Tortora, M; Palmieri, G; Giannarelli, D; Aieta, M; Assalone, P; Attademo, L; Avallone, A; Bloise, F; Bosso, D; Borzillo, V; Buono, G; Calderoni, G; Caputo, F; Cartenì, G; Cavallero, D; Cavo, A; Ciardiello, F; Conca, R; Conteduca, V; De Falco, S; De Felice, M; De Laurentiis, M; De Placido, P; De Placido, S; De Santo, I; De Stefano, A; Della Corte, CM; Di Franco, R; Di Lauro, V; Fabbrocini, A; Federico, P; Festino, L; Giordano, P; Giuliano, M; Gridelli, C; Grimaldi, AM; Lia, M; Marretta, AL; Massa, V; Mennitto, A; Merler, S; Merz, V; Messina, C; Messina, M; Milano, M; Minisini, AM; Montesarchio, V; Morabito, A; Morgillo, F; Mucci, B; Nappi, L; Napolitano, F; Paciolla, I; Pagliuca, M; Palmieri, G; Parola, S; Pepe, S; Petrillo, A; Piantedosi, F; Piccin, L; Picozzi, F; Pietroluongo, E; Pignata, S; Prati, V; Riccio, V; Rosanova, M; Rossi, A; Russo, A; Salati, M; Santabarbara, G; Sbrana, A; Simeone, E; Silvestri, A; Spada, M; Tarantino, P; Taveggia, P; Tomei, F; Vincenzo, T; Trapani, D; Trojanello, C; Vanella, V; Vari, S; Ventriglia, J; Vitale, MG; Vitiello, F; Vivaldi, C; von Arx, C; Zacchi, F; Zampiva, I; Zivi, A; Daniele, B; Ascierto, PA; SCITO (Società Campana di ImmunoTerapia Oncologica)
      Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors ...
    • Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. 

      Minchom, A; Yuan, W; Crespo, M; Gurel, B; Figueiredo, I; Wotherspoon, A; Miranda, S; Riisnaes, R; Ferreira, A; Bertan, C; Pereira, R; Clarke, M; Baker, C; Ang, JE; Fotiadis, N; Tunariu, N; Carreira, S; Popat, S; O'Brien, M; Banerji, U; de Bono, J; Lopez, J (2020-03)
      Background This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge.Case presentation A 77-year-old woman with advanced epithelioid ...
    • Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. 

      Ameratunga, M; Chénard-Poirier, M; Moreno Candilejo, I; Pedregal, M; Lui, A; Dolling, D; Aversa, C; Ingles Garces, A; Ang, JE; Banerji, U; Kaye, S; Gan, H; Doger, B; Moreno, V; de Bono, J; Lopez, J (2018-01)
      BACKGROUND:Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought ...
    • Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. 

      Popat, S; Mellemgaard, A; Reck, M; Hastedt, C; Griebsch, I (2017-06)
      Patients & methods We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer.Results ...
    • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, K; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Iglesias Docampo, LC; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Monga, M; Lynch, M; Geese, WJ; Kopit, J; Shaw, JW; Gillison, ML (2016-11)
      Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 ...
    • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Docampo, LCI; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Lynch, M; Jayaprakash, V; Li, L; Gillison, ML (2018-06)
      OBJECTIVES:We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory ...
    • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. 

      Flynn, MJ; Larkin, JMG (2017-10)
      Introduction Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy ...